Longevity
Cartalax
Khavinson cartilage bioregulator
Khavinson short peptide bioregulator
This Cartalax entry draws on 3 cited sources published 2020 to 2021. The evidence available is graded Russian Research on this site's scale. Dosing is reported as described in the literature rather than as guidance. Sources checked .
At a glance
- Class
- Khavinson short peptide bioregulator
- Drug class
- Longevity
- Structure
- Tetrapeptide Ala-Glu-Asp-Leu
- Route
- Oral
- Half-life
- Short (minutes)
- Evidence tier
- Russian Research
- Availability
- Research
- Research depth
- 3 indexed citations →
Mechanism of action
Tissue-specific gene expression modulation in chondrocytes
Reported areas of research
Cartilage/musculoskeletal support
Items above describe areas studied in published peptide literature, not approved indications. Most peptides catalogued here are not FDA-approved for human use.
Dosage protocols reported in literature
Oral capsule 1-2x daily
Reported research dosing only. This is not a clinical recommendation. Consult a qualified clinician before any human use.
Known concerns and limitations
Limited Western evidence
Compared with
Cartalax has published head-to-head comparisons with 16 compounds that share its pharmacological class: mechanism, half-life, reported research dosing, evidence tier and regulatory status side by side.
- Cartalax vs Bronchogen
- Cartalax vs Cardiogen
- Cartalax vs Chonluten
- Cartalax vs Cortagen
- Cartalax vs Crystagen
- Cartalax vs Epitalon
- Cartalax vs Livagen
- Cartalax vs Ovagen
- Cartalax vs Pancragen
- Cartalax vs Pinealon
- Cartalax vs Prostamax
- Cartalax vs Testagen
- Cartalax vs Thymagen
- Cartalax vs Vesilute
- Cartalax vs Vesugen
- Cartalax vs Vilon
Frequently asked questions
What dosing is reported for Cartalax in research literature?
Published peptide research reports the following dosing approach for Cartalax: Oral capsule 1-2x daily. This is a research reference, not a clinical recommendation.
How is Cartalax administered in research?
Cartalax is administered via the following routes in published studies: Oral.
What is the reported half-life of Cartalax?
No measured half-life for Cartalax is reported in the literature catalogued here. The catalog describes it as: Short (minutes).
Is Cartalax FDA-approved?
No. Cartalax is not an FDA-approved drug. PeptideHelper.org catalog status: Research.
What level of evidence supports Cartalax?
The current evidence base for Cartalax is best characterised as: Russian Research. See the methodology page for the full evidence-tier rubric.
What side effects are reported for Cartalax?
Known concerns reported in the literature for Cartalax include: Limited Western evidence. Always consult a qualified clinician before any human use.
Is there anyone who should not use Cartalax?
No formal contraindications are established for Cartalax, because it is not an FDA-approved medicine and no approved label exists to define them. That is an absence of regulatory review rather than evidence of safety. Reported concerns from the literature are: Limited Western evidence. Always consult a qualified clinician before any human use.
How does Cartalax work?
The mechanism of action reported for Cartalax in the literature: Tissue-specific gene expression modulation in chondrocytes.
What is Cartalax studied for?
Cartalax has been studied in the published literature for: Cartilage/musculoskeletal support. These are areas of research, not established clinical uses unless the compound is FDA-approved for them.
What is Cartalax?
Cartalax is classified as: Khavinson short peptide bioregulator. Also known as: Khavinson cartilage bioregulator.
Drug class
- Khavinson peptides, see all peptides tagged Khavinson.
Research focus area
All peptides studied for Longevity, ranked by evidence tier and regulatory status.
Primary sources
- Khavinson VK et al. Peptide regulation of gene expression — a systematic review. Molecules 2021. PMID 34834147
- Khavinson V et al. Peptide regulation of cell differentiation. Stem Cell Rev Rep 2020. PMID 31808038
- Note: Primary literature on this peptide is published largely in Russian gerontology journals (Adv Gerontol, Bull Eksp Biol Med). English-indexed sources are limited to comprehensive Khavinson-laboratory reviews; entry confidence is correspondingly lower.
Open the full interactive PeptideHelper.org reference to compare peptides side-by-side, evaluate stacks, and explore the catalog.
Spot an error or a missing source on this page? Suggest a correction. Corrections are logged and surfaced in the next review.
Loading interactive view…